PEGylated long circulating nanostructured lipid carriers for Amoitone B: Preparation, cytotoxicity and intracellular uptake

Journal of Colloid and Interface Science

Volumn 428, Issue , 2014, Pages 49-56

  Luan, Jingjing ^a   Yang, Xiaoye ^a   Chu, Lianjun ^b   Xi, Yanwei ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

^b DEZHOU UNIVERSITY   (China)

Author keywords

Amoitone B; Apoptosis; Intracellular uptake; Nanostructured lipid carriers; PEG

Indexed keywords

ASSAYS; CELL DEATH; DISEASES; EMULSIFICATION; FLUORESCENCE; POLYETHYLENE GLYCOLS;

ANTICANCER ACTIVITIES; CYTOTOXICITY ASSAYS; HUMAN COLON CANCER; INTRACELLULAR UPTAKE; MORPHOLOGICAL CHANGES; MORPHOLOGY CHANGES; NANOSTRUCTURED LIPID CARRIERS; SYNTHESIZED DERIVATIVES;

CYTOTOXICITY;

4',6 DIAMIDINO 2 PHENYLINDOLE; AMOITONE B; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL; NANOSTRUCTURED LIPID CARRIER; PEGYLATED LONG CIRCULATING NANOSTRUCTURED LIPID CARRIER; PROPIDIUM IODIDE; RHODAMINE B; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; N-AMYL 2-(3,5-DIHYDROXY-2-(1-NONANOYL)PHENYL)ACETATE; NANOMATERIAL; PHENYLACETIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; CELL GROWTH; CELL VIABILITY; COLON CANCER; COMPARATIVE STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG HALF LIFE; DRUG SYNTHESIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CANCER; MTT ASSAY; PRIORITY JOURNAL; SOLUBILITY; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; LIVER NEOPLASMS; PARTICLE SIZE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG CARRIERS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NANOSTRUCTURES; PARTICLE SIZE; PHENYLACETATES; POLYETHYLENE GLYCOLS;

EID: 84899914904     PISSN: 00219797     EISSN: 10957103     Source Type: Journal    
DOI: 10.1016/j.jcis.2014.04.036     Document Type: Article

References (30)

1. Cho S.D., Yoon K., Chintharlapalli S., Abdelrahim M., Lei P., Hamilton S., Khan S., Ramaiah S.K., Safe S. Cancer Res. 2007, 67:674-683.
2. Sibayama-Imazu T., Fujisawa Y., Masuda Y., Aiuchi T., Nakajo S., Itabe H., Nakaya K. J. Cancer Res. Clin. Oncol. 2008, 134:803-812.
3. Wu Q., Liu S., Ye X.-F., Huang Z.-W., Su W.-J. Carcinogenesis 2002, 23:1583-1592.
4. Kolluri S.K., Bruey-Sedano N., Cao X., Lin B., Lin F., Han Y.-H., Dawson M.I., Zhang X.-K. Mol. Cell. Biol. 2003, 23:8651-8667.
5. Giguère V. Endocr. Rev. 1999, 20:689-725.
6. Maruyama K., Tsukada T., Ohkura N., Bandoh S., Hosono T., Yamaguchi K. Int. J. Oncol. 1998, 12:1237-1243.
7. Zhan Y., Du X., Chen H., Liu J., Zhao B., Huang D., Li G., Xu Q., Zhang M., Weimer B.C., Chen D., Cheng Z., Zhang L., Li Q., Li S., Zheng Z., Song S., Huang Y., Ye Z., Su W., Lin S.-C., Shen Y., Wu Q. Nat. Chem. Biol. 2008, 4:548-556.
8. Brady S.F., Wagenaar M.M., Singh M.P., Janso J.E., Clardy J. Org. Lett. 2000, 2:4043-4046.
9. Hao L., Wang X., Zhang D., Xu Q., Song S., Wang F., Li C., Guo H., Liu Y., Zheng D., Zhang Q. Int. J. Pharm. 2012, 433:157-164.
10. Liu J.j., Zeng H.n., Zhang L.r., Zhan Y.y., Chen Y., Wang Y., Wang J., Xiang S.h., Liu W.j., Wang W.j., Chen H.z., Shen Y.m., Su W.j., Huang P.q., Zhang H.k., Wu Q. Cancer Res. 2010, 70:3628-3637.
11. Müller R., Radtke M., Wissing S. Int. J. Pharm. 2002, 242:121-128.
12. Müller R., Radtke M., Wissing S. Adv. Drug Deliv. Rev. 2002, 54:S131-S155.
13. Weber S., Zimmer A., Pardeike J. Eur. J. Pharm. Biopharm. 2013, http://dx.doi.org/10.1016/j.ejpb.2013.08.013
14. Selvamuthukumar S., Velmurugan R. Lipids Health Dis. 2012, 11:159.
15. Das S., Ng W.K., Tan R.B.H. Eur. J. Pharm. Sci. 2012, 47:139-151.
16. Jenning V., Thünemann A.F., Gohla S.H. Int. J. Pharm. 2000, 199:167-177.
17. Darwis Y., Ali Khan A., Mudassir J., Mohtar N. Int. J. Nanomed. 2013, 2733.
18. Gao W., Xiang B., Meng T.-T., Liu F., Qi X.-R. Biomaterials 2013, 34:4137-4149.
19. Yang X.-Y., Li Y.-X., Li M., Zhang L., Feng L.-X., Zhang N. Cancer Lett. 2013, 334:338-345.
20. Blanco E., Sangai T., Hsiao A., Ferrati S., Bai L., Liu X., Meric-Bernstam F., Ferrari M. Cancer Lett. 2013, 334:245-252.
21. Shen J., Wang Y., Ping Q., Xiao Y., Huang X. J. Controlled Release 2009, 137:217-223.
22. Jia L., Shen J., Zhang D., Duan C., Liu G., Zheng D., Tian X., Liu Y., Zhang Q. Int. J. Biol. Macromol. 2012, 50:523-529.
23. Sheng Y., Liu C., Yuan Y., Tao X., Yang F., Shan X., Zhou H., Xu F. Biomaterials 2009, 30:2340-2348.
24. Zhang Y., Kohler N., Zhang M. Biomaterials 2002, 23:1553-1561.
25. Luan J., Zhang D., Hao L., Qi L., Liu X., Guo H., Li C., Guo Y., Li T., Zhang Q., Zhai G. Colloids Surf., B 2014, 114:255-260.
26. des Rieux A., Fievez V., Momtaz M., Detrembleur C., Alonso-Sande M., Van Gelder J., Cauvin A., Schneider Y.-J., Préat V. J. Controlled Release 2007, 118:294-302.
27. des Rieux A., Fievez V., Théate I., Mast J., Préat V., Schneider Y.-J. Eur. J. Pharm. Sci. 2007, 30:380-391.
28. Zheng D., Wang Y., Zhang D., Liu Z., Duan C., Jia L., Wang F., Liu Y., Liu G., Hao L. Cancer Lett. 2011, 307:158-164.
29. Sandri G., Bonferoni M.C., Rossi S., Ferrari F., Gibin S., Zambito Y., Di Colo G., Caramella C. Eur. J. Pharm. Biopharm. 2007, 65:68-77.
30. Wang Y., Ma Y., Zheng Y., Song J., Yang X., Bi C., Zhang D., Zhang Q. Int. J. Pharm. 2013, 441:728-735.